TY - JOUR
T1 - Genetic correlation between smoking behaviors and schizophrenia
AU - Hartz, Sarah M.
AU - Horton, Amy C.
AU - Hancock, Dana B.
AU - Baker, Timothy B.
AU - Caporaso, Neil E.
AU - Chen, Li Shiun
AU - Hokanson, John E.
AU - Lutz, Sharon M.
AU - Marazita, Mary L.
AU - McNeil, Daniel W.
AU - Pato, Carlos N.
AU - Pato, Michele T.
AU - Johnson, Eric O.
AU - Bierut, Laura J.
N1 - Funding Information:
We thank the many participants of these studies. This work was supported by the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) grant numbers K08 032680 , R01 DA035825 , R01 DA036583, R01 HL089897, R01 HL089856, K01 HL125858, R01-DE014899 and U01-DE018903 . Funding support for the nicotine dependence study samples were previously described ( Hancock et al., 2015 ). The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health. The COPDGene® project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion.
Funding Information:
We thank the many participants of these studies. This work was supported by the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) grant numbers K08 032680, R01 DA035825, R01 DA036583, R01 HL089897, R01 HL089856, K01 HL125858, R01-DE014899 and U01-DE018903. Funding support for the nicotine dependence study samples were previously described (Hancock et al., 2015). The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health. The COPDGene? project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/4
Y1 - 2018/4
N2 - Nicotine dependence is highly comorbid with schizophrenia, and the etiology of the comorbidity is unknown. To determine whether there is a genetic correlation of smoking behavior with schizophrenia, genome-wide association study (GWAS) meta-analysis results from five smoking phenotypes (ever/never smoker (N = 74,035), age of onset of smoking (N = 28,647), cigarettes smoked per day (CPD, N = 38,860), nicotine dependence (N = 10,666), and current/former smoker (N = 40,562)) were compared to GWAS meta-analysis results from schizophrenia (N = 79,845) using linkage disequilibrium (LD) score regression. First, the SNP heritability (h2 g) of each of the smoking phenotypes was computed using LD score regression (ever/never smoker h2 g = 0.08, age of onset of smoking h2 g = 0.06, CPD h2 g = 0.06, nicotine dependence h2 g = 0.15, current/former smoker h2 g = 0.07, p < 0.001 for all phenotypes). The SNP heritability for nicotine dependence was statistically higher than the SNP heritability for the other smoking phenotypes (p < 0.0005 for all two-way comparisons). Next, a statistically significant (p < 0.05) genetic correlation was observed between schizophrenia and three of the five smoking phenotypes (nicotine dependence rg = 0.14, CPD rg = 0.12, and ever/never smoking rg = 0.10). These results suggest that there is a component of common genetic variation that is shared between smoking behaviors and schizophrenia.
AB - Nicotine dependence is highly comorbid with schizophrenia, and the etiology of the comorbidity is unknown. To determine whether there is a genetic correlation of smoking behavior with schizophrenia, genome-wide association study (GWAS) meta-analysis results from five smoking phenotypes (ever/never smoker (N = 74,035), age of onset of smoking (N = 28,647), cigarettes smoked per day (CPD, N = 38,860), nicotine dependence (N = 10,666), and current/former smoker (N = 40,562)) were compared to GWAS meta-analysis results from schizophrenia (N = 79,845) using linkage disequilibrium (LD) score regression. First, the SNP heritability (h2 g) of each of the smoking phenotypes was computed using LD score regression (ever/never smoker h2 g = 0.08, age of onset of smoking h2 g = 0.06, CPD h2 g = 0.06, nicotine dependence h2 g = 0.15, current/former smoker h2 g = 0.07, p < 0.001 for all phenotypes). The SNP heritability for nicotine dependence was statistically higher than the SNP heritability for the other smoking phenotypes (p < 0.0005 for all two-way comparisons). Next, a statistically significant (p < 0.05) genetic correlation was observed between schizophrenia and three of the five smoking phenotypes (nicotine dependence rg = 0.14, CPD rg = 0.12, and ever/never smoking rg = 0.10). These results suggest that there is a component of common genetic variation that is shared between smoking behaviors and schizophrenia.
KW - Genetic correlation
KW - Nicotine dependence
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85015789839&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2017.02.022
DO - 10.1016/j.schres.2017.02.022
M3 - Article
C2 - 28285025
AN - SCOPUS:85015789839
SN - 0920-9964
VL - 194
SP - 86
EP - 90
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -